Back to Archived News
Third HDL Selective Delipidation Patent Granted to Lipid Sciences
Tuesday, July 01, 2008
Lipid Sciences, Inc. (Nasdaq: LIPD) continues to build on its already extensive HDL Selective Delipidation intellectual property portfolio with the issuance of U.S. Patent No. 7,393,826. This third patent, dated July 1, 2008, further extends the depth of patent coverage surrounding the Company's HDL Therapy platform, and in particular, the proprietary selective delipidation process. These particular patents are a critical component of the Company's strategic plan to maximize the value of this strong IP position and the recent clinical trial data to pursue a corporate partnership related to Lipid Sciences' HDL Selective Delipidation.
Dr. S. Lewis Meyer, President and Chief Executive Officer of Lipid Sciences, noted, "We have seen the sudden devastating effect of vulnerable plaque rupture with the recent death of Tim Russert -- the host of 'Meet the Press.' Our systemic selective delipidation therapy reduces the likelihood that vulnerable plaque deposited on the wall of the coronary artery will rupture and cause a fatal heart attack. Unfortunately, for about 38% of those patients suffering a heart attack, the first symptom of their cardiovascular disease is death. Our Selective Delipidation process 'energizes' a patient's own HDL particles to pick up excess lipids from plaque in the arterial walls and transport those lipids to the liver to be processed and naturally excreted from the body. Our proprietary process has the potential to address a significant unmet clinical need in cardiovascular disease. Statistics show that someone is having a heart attack every 26 seconds...with a better than 20% chance of having another coronary event within 18 months. We at Lipid Sciences believe that we are well positioned to be the first to market with a unique approach to HDL Therapy."
Lipid Sciences, Inc. is a development-stage biotechnology company engaged in the research and development of products and processes intended to treat major medical indications, in which lipids, or fat components, play a key role. The Company's HDL Therapy platform (HDL Mimetic Peptides and HDL Selective Delipidation) aims to develop treatments to reverse atherosclerosis, a systemic disease caused by the build-up of cholesterol-filled plaques in the vascular system and, most critically, in the coronary arteries. Regression of such plaques may have a major impact on reducing the risk of acute coronary events. The Company's Viral Immunotherapy platform focuses on the removal of the lipid coatings from lipid-enveloped viruses and other lipid-containing infectious agents by applying Lipid Sciences' proprietary delipidation technologies. The Company believes that removing the virus' protective lipid coating enhances the processing and presentation of viral proteins to stimulate the body's immune system to effectively fight the disease. Conditions that could potentially be impacted by these technologies include HIV, SARS, and influenza. In addition, Lipid Sciences believes that this Viral Immunotherapy platform also has applicability to a wide range of viruses impacting animal health -- a diverse market with diseases affecting both food and companion animals.
Forward-Looking Statements
This release contains forward-looking statements concerning plans, objectives, goals, strategies, study results, anticipations, expectations, future events or performance as well as all other statements that are not statements of historical fact. The forward-looking statements contained in this release reflect our current beliefs and expectations on the date of this release. Actual results, performance or outcomes may differ materially from what is expressed in the forward-looking statements. Readers should refer to the documents filed by us with the SEC, specifically the most recent reports on Form 10-K and Form 10-Q which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. In addition to those risk factors, other factors that could cause actual results to differ materially include the following: our inability to obtain adequate funds; our technologies not proving to be safe or effective; our inability to obtain regulatory approval of our technologies, which are only in the clinical development stage; delay or failure to complete clinical studies; our dependence on our license agreement with Aruba International B.V.; our reliance on collaborations with strategic partners and consultants; our reliance on key suppliers to provide the material necessary to conduct successful pre-clinical and clinical studies; competition in our industry, including the development of new products by others that may provide alternative or better therapies; failure to secure and enforce our intellectual property rights; risks associated with use of biological and hazardous materials; acceptance of our potential products by healthcare providers and patients; and our dependence on key personnel.
This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent reports on Form 10-K and Form 10-Q. Copies are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at www.sec.gov. Lipid Sciences assumes no obligation to update the forward-looking statements included in this document.
Press releases for Lipid Sciences, Inc. are available on our website: www.lipidsciences.com. To receive the Company's press releases via email, please contact: info@lipidsciences.com.
Back to Archived News
